Skip to main content

Table 3 Comparison of commonly used allogeneic NK cell sources

From: NK cell-based cancer immunotherapy: from basic biology to clinical development

NK source



PB-NK cells

Relatively easy to collect

Good in vivo expansion

Good clinical track record

Heterogeneous cell population

Challenging to genetically modify

Can only give one dose

UB-NK cells

NK Progenitors and CD34 + present

Higher percentage of NK cells

The ability to cryopreserve UCB

Heterogeneous cell population

NK92 cells

Defined, homogeneous cell population

Easy to expand

Easy to genetically modify

Can give multiple doses

Tumor cells Irradiated

Lack certain receptors, e.g., CD16

limited in vivo expansion

iPSC-NK cells

Defined, homogeneous cell population

Circumvent issues with donor sourced cells (donor selection, contaminating T, B)

Potential for in depth preclinical testing

Defined genetic makeup

Easy to genetically modify at iPSC stage

Can give multiple doses

Can engineer multiple enhancements

Don’t need to irradiate- good in vivo survival

Suitable for “off-the-shelf” multicancer NK cell therapy

More complicated to produce